Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges ...

Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

The DVLA regulations set out a list of 110 medical conditions that drivers are required to report to the authorities, with ...

The DVLA has issued a warning to drivers who have certain medical conditions, as it's a legal requirement to declare these to ...

Axsome Therapeutics (NASDAQ:AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with ...

According to experts, there are a number of medical conditions that drivers have to tell the DVLA about or risk facing a ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Recent advice from one of the UK's leading online platforms for selling used cars, BigWantsYourCar.com, stresses the ...

Motorists could be fined up to £1,000 for failing to disclose medical conditions to the DVLA, according to experts at ...

Driving with certain conditions could put you or other road users at risk, so it's vital that you let the DVLA know about ...

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, ...

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a ...